AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1412762529-2fb014f1b6534c44bc40e451aad3e66c.jpg "<div>Accounting vs. Auditing: What's the Difference?</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-905523822-6ce8d6962dc5413294e395ee3d3890f1-1b1de6e34f694a40a96495cea874e604.jpg "Spend or Save: Should I Pay Off My Mortgage, or Invest for Retirement?")